NUTRACEUTICALS IN DYSLIPIDEMIA: AN ALTERNATIVE APPROACH
DOI:
https://doi.org/10.22159/ajpcr.2017.v10i1.15360Abstract
Dyslipidemia is a well-known modifiable risk factor for preventing cardiovascular diseases. The present therapy mainly aiming at pharmacological treatment to reduce lipid levels may not be effective in each individual to meet the target levels. Diet and lifestyle modification has an important role in treating such chronic illnesses. Nutraceuticals, which are derived from food products, provide one such alternate therapy for the management of dyslipidemia. Some of them have proven to be effective for treating dyslipidemia while others require further studies. Much work is still required to understand the pharmacokinetics and mechanism of action of these products. Nutraceuticals hold promise in the clinical management of dyslipidemia and can be used as primary preventive therapy as more evidence from studies comes in light.
Keywords: Dyslipidemia, Nutraceuticals, Cardiovascular disease, Statins.
Downloads
References
Available from: http://www.who.int/mediacentre/factsheets/fs317/en.
Tian N, Penman AD, Mawson AR, Manning RD Jr, Flessner MF. Association between circulating specific leukocyte types and blood pressure: The atherosclerosis risk in communities (ARIC) study. J Am Soc Hypertens 2010;4(6):272-83.
Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376(9753):1670-81.
Gillespie CD, Keenan NL, Miner JB, Hong Y; Centers for Disease Control and Prevention (CDC). Screening for lipid disorders among adults – National Health and Nutrition Examination Survey, United States, 2005-2008. MMWR Suppl 2012;61(2):26-31.
Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics--2012 update: A report from the American Heart Association. Circulation 2012;125(1):e2-20.
Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000;343:16-22.
Kris-Etherton PM, Etherton TD, Carlson J, Gardner C. Recent discoveries in inclusive food-based approaches and dietary patterns for reduction in risk for cardiovascular disease. Curr Opin Lipidol
;13(4):397-407.
Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, et al. Efficacy and safety of statin treatment for cardiovascular disease: A network meta-analysis of 170,255 patients from 76 randomized trials. QJM 2011;104(2):109-24.
Tapas AR, Sakarkar DM, Kakde RB. Flavonoids as nutraceuticals: A review. Trop J Pharm Res 2008;7(3):1089-99.
Rajasekaran A, Sivagnanam G, Xavier R. Nutraceuticals as therapeutic agents: A Review. Res J Pharm Tech 2008;1:328-40.
DeFelice SL. The nutraceutical revolution: Its impact on food industry R&D. Trends Food Sci Technol 1995;6(2):59-61.
Kalra EK. Nutraceutical – definition and introduction. AAPS PharmSci 2003;5(3):E25.
Available from:http://www.fssai.gov.in/Portals/0/Pdf/Draft_ Regulation_on_Nutraceuticals WTO_23_07_2015.pdf.
Ciccone MM, Scicchitano P, Gesualdo M, Zito A, Carbonara S, Ricci G, et al. The role of omega-3 polyunsaturated fatty acids supplementation in childhood: A review. Recent Pat Cardiovasc Drug Discov 2013;8(1):42-55.
Marazzi G, Cacciotti L, Pelliccia F, Iaia L, Volterrani M, Caminiti G, et al. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Adv Ther 2011;28(12):1105-13.
Sirtori CR, Galli C, Anderson JW, Arnoldi A. Nutritional and nutraceutical approaches to dyslipidemia and atherosclerosis prevention: Focus on dietary proteins. Atherosclerosis 2009;203(1):8-17.
Chen CH, Yang JC, Uang YS, Lin CJ. Improved dissolution rate and oral bioavailability of lovastatin in red yeast rice products. Int J Pharm 2013;444(1-2):18-24.
Li Y, Guo C, Yang J, Wei J, Xu J, Cheng S. Evaluation of antioxidant properties of pomegranate peel extract in comparison with pomegranate pulp extract. Food Chem 2006;96(2):254-60.
Kelsey NA, Wilkins HM, Linseman DA. Nutraceutical antioxidants as novel neuroprotective agents. Molecules 2010;15(11):7792-814.
Augustin MA, Sanguansri L, Lockett T. Nano- and micro-encapsulated systems for enhancing the delivery of resveratrol. Ann N Y Acad Sci 2013;1290:107-12.
Vastano BC, Chen Y, Zhu N, Ho CT, Zhou Z, Rosen RT. Isolation and identification of stilbenes in two varieties of Polygonum cuspidatum. J Agric Food Chem 2000;48(2):253-6.
Cho IJ, Ahn JY, Kim S, Choi MS, Ha TY. Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters. Biochem Biophys Res Commun 2008;367(1):190-4.
Berrougui H, Grenier G, Loued S, Drouin G, Khalil A. A new insight into resveratrol as an atheroprotective compound: Inhibition of lipid peroxidation and enhancement of cholesterol efflux. Atherosclerosis 2009;207(2):420-7.
Mader I, Wabitsch M, Debatin KM, Fischer-Posovszky P, Fulda S. Identification of a novel proapoptotic function of resveratrol in fat cells: SIRT1-independent sensitization to TRAIL-induced apoptosis. FASEB J 2010;24(6):1997-2009.
Chen Q, Wang E, Ma L, Zhai P. Dietary resveratrol increases the expression of hepatic 7a-hydroxylase and ameliorates hypercholesterolemia in high-fat fed C57BL/6J mice. Lipids Health Dis
;11:56.
Spanier G, Xu H, Xia N, Tobias S, Deng S, Wojnowski L, et al. expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4). J Physiol Pharmacol
;60 Suppl 4:111-6.
Szewczuk LM, Penning TM. Mechanism-based inactivation of COX-1 by red wine m-hydroquinones: A structure-activity relationship study. J Nat Prod 2004;67(11):1777-82.
Frémont L. Biological effects of resveratrol. Life Sci 2000;66(8):663-73.
Shen MY, Hsiao G, Liu CL, Fong TH, Lin KH, Chou DS, et al. Inhibitory mechanisms of resveratrol in platelet activation: Pivotal roles of p38 MAPK and NO/cyclic GMP. Br J Haematol 2007;139(3):475-85.
Houston M. The role of nutraceutical supplements in the treatment of dyslipidemia. J Clin Hypertens (Greenwich) 2012;14(2):121-32.
Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K. Clinical trials of resveratrol. Ann N Y Acad Sci 2011;1215:161-9.
Miksicek RJ. Estrogenic flavonoids: Structural requirements for biological activity. Proc Soc Exp Biol Med 1995;208(1):44-50.
Nijjar PS, Burke FM, Bloesch A, Rader DJ. Role of dietary supplements in lowering low-density lipoprotein cholesterol: A review. J Clin Lipidol 2010;4(4):248-58.
Baum JA, Teng H, Erdman JW Jr, Weigel RM, Klein BP, Persky VW, et al. Long-term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women. Am J Clin Nutr
;68(3):545-51.
Harland JI, Haffner TA. Systematic review, meta-analysis and regression of randomised controlled trials reporting an association between an intake of circa 25 g soya protein per day and blood cholesterol. Atherosclerosis 2008;200(1):13-27.
Reynolds K, Chin A, Lees KA, Nguyen A, Bujnowski D, He J. A meta-analysis of the effect of soy protein supplementation on serum lipids. Am J Cardiol 2006;98(5):633-40.
Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995;333(5):276-82.
Food labeling: Health claims; Soy protein and coronary heart disease. Food and Drug Administration, HHS. Final rule. Fed Regist 1999;64(206):57700-33.
Lovati MR, Manzoni C, Corsini A, Granata A, Frattini R, Fumagalli R, et al. Low density lipoprotein receptor activity is modulated by soybean globulins in cell culture. J Nutr 1992;122(10):1971-8.
Lovati MR, Manzoni C, Corsini A, Granata A, Fumagalli R, Sirtori CR.
S globulin from soybean is metabolized in human cell cultures by a specific uptake and degradation system. J Nutr 1996;126(11):2831-42.
Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: Evaluating the risks and the benefits. JAMA 2006;296(15):1885-99.
Calder PC. n-3 Fatty acids and cardiovascular disease: Evidence explained and mechanisms explored. Clin Sci (Lond) 2004;107(1):1-11.
Schmidt S, Willers J, Stahl F, Mutz KO, Scheper T, Hahn A, et al. Regulation of lipid metabolism-related gene expression in whole blood cells of normo- and dyslipidemic men after fish oil supplementation. Lipids Health Dis 2012;11:172.
Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI - Prevenzione trial Gruppo Italiano per lo Studio della Sopravvivenza nell’ Infarto miocardico. Lancet 1999;354(9177):447-55.
Houston MC, Fazio S, Chilton FH, Wise DE, Jones KB, Barringer TA, et al. Nonpharmacologic treatment of dyslipidemia. Prog Cardiovasc Dis 2009;52(2):61-94.
American Heart Association Nutrition Committee, Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, et al. Diet and lifestyle recommendations revision 2006: A scientific statement from the American Heart Association Nutrition Committee. Circulation 2006;114(1):82-96.
Needleman P, Raz A, Minkes MS, Ferrendelli JA, Sprecher H. Triene prostaglandins: Prostacyclin and thromboxane biosynthesis and unique biological properties. Proc Natl Acad Sci U S A 1979;76(2):944-8.
Zeng L, An S, Goetzl EJ. EP4/EP2 receptor-specific prostaglandin E2 regulation of interleukin-6 generation by human HSB.2 early T cells. J Pharmacol Exp Ther 1998;286(3):1420-6.
Lau CW, Yao XQ, Chen ZY, Ko WH, Huang Y. Cardiovascular actions of berberine. Cardiovasc Drug Rev 2001;19(3):234-44.
Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004;10(12):1344-51.
Cicero AF, Ertek S. Metabolic and cardiovascular effects of berberine: From preclinical evidences to clinical trial results. Clin Lipidol 2009;4(5):553-63.
Brusq JM, Ancellin N, Grondin P, Guillard R, Martin S, Saintillan Y, et al. Inhibition of lipid synthesis through activation of AMP kinase: An additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 2006;47(6):1281-8.
Dong H, Zhao Y, Zhao L, Lu F. The effects of berberine on blood lipids: A systemic review and meta-analysis of randomized controlled trials. Planta Med 2013;79(6):437-46.
Derosa G, Maffioli P, Cicero AF. Berberine on metabolic and cardiovascular risk factors: An analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther 2012;12(8):1113-24.
Ma J, Li Y, Ye Q, Li J, Hua Y, Ju D, et al. Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem 2000;48(11):5220-5.
Went FA. Monascus purpureus fungus angquac the new thelobolee. Ann Soc Nat Bot 1895;8:1-17.
Endo A, Monacolin K. A new hypocholesterolemic agent produced by a Monascus species. J Antibiot (Tokyo) 1979;32(8):852-4.
Journoud M, Jones PJ. Red yeast rice: A new hypolipidemic drug. Life Sci 2004;74(22):2675-83.
Lin CC, Li TC, Lai MM. Efficacy and safety of Monascus purpureus went rice in subjects with hyperlipidemia. Eur J Endocrinol 2005;153(5):679-86.
Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients: A randomized trial. Ann Intern Med 2009;150(12):830-9, W147-9.
Halbert SC, French B, Gordon RY, Farrar JT, Schmitz K, Morris PB, et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 2010;105(2):198-204.
Available from: http://www.fda.gov/OHRMS/DOCKETS/dailys/01/ Jun01/061101/let0494.pdf.
Olszanecki R, Jawien J, Gajda M, Mateuszuk L, Gebska A, Korabiowska M, et al. Effect of curcumin on atherosclerosis in apoE/ LDLR-double knockout mice. J Physiol Pharmacol 2005;56(4):627-35.
Peschel D, Koerting R, Nass N. Curcumin induces changes in expression of genes involved in cholesterol homeostasis. J Nutr Biochem 2007;18(2):113-9.
Soni KB, Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol 1992;36(4):273-5.
El Sohaimy SA. Functional foods and nutraceuticals-modern approach to food science. World Appl Sci J 2012;20(5):691-708.
Available from: http://www.researchandmarkets.com/reports/3600554/
nutraceuticals-market-functional-food-dietry.
Available from: http://www.naturalproductsinsider.com/ articles/2014/05/indian-nutraceutical-market-is-filled-with-promis. aspx/.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
